RxDoctor Payments Data

Matthew Perkins, MD

Internal Medicine · Bossier City, LANPI 1215496690

Payments from drug & device makers

$2,467in general payments, 2019–2025

Across 116 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$628
  • Actelion Pharmaceuticals US, Inc.$499
  • Boehringer Ingelheim$308
  • GSK$229
  • Insmed, Inc.$148
  • Olympus America Inc.$137
  • plus $518 from 12 others

What the payments were for

  • Food & beverage$2,30994%
  • Education$1586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,467 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,014
Medicare patients
37
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$35,951
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$14,045
Incruse ElliptaUmeclidinium Bromide21$10,505
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,638
Spiriva HandihalerTiotropium Bromide11$6,497
Advair HfaFluticasone Propion/Salmeterol11$4,302
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,535
SymbicortBudesonide/Formoterol Fumarate13$2,978
Albuterol Sulfate HfaAlbuterol Sulfate90$2,948
Fluticasone Propionate11$113
Montelukast Sodium15$48
Pantoprazole Sodium13$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$229$54,09487 claims
Boehringer IngelheimStiolto Respimat$308$14,04525 claims
AstraZenecaSymbicort$628$2,97813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →